Increasingly, targeted therapies are becoming available for patients whose cancers have mutations in certain 'driver' genes that are known to be involved in cancer growth. However, most cancer patients have tumors without these mutations or other changes in their DNA. These patients will be the focus of the new WINTHER clinical trial. The study will compare biopsy samples of the patients’ tumors with healthy tissue samples to see how much they differ. This information, along with examinations of other molecules involved in gene expression called RNA and microRNA, will be used to select the existing cancer treatment most likely to benefit the patient based on a novel scoring system.